DOP2013000035A - Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico - Google Patents

Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico

Info

Publication number
DOP2013000035A
DOP2013000035A DO2013000035A DO2013000035A DOP2013000035A DO P2013000035 A DOP2013000035 A DO P2013000035A DO 2013000035 A DO2013000035 A DO 2013000035A DO 2013000035 A DO2013000035 A DO 2013000035A DO P2013000035 A DOP2013000035 A DO P2013000035A
Authority
DO
Dominican Republic
Prior art keywords
acid derivatives
enantiomeric forms
procedure
diaminopropionic acid
prepare
Prior art date
Application number
DO2013000035A
Other languages
English (en)
Inventor
Joerg Rieke-Zapp
Claus-Dieter Graf
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000035(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2013000035A publication Critical patent/DOP2013000035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Abstract

La invención se refiere a un procedimiento para preparar las formas enantiomèricas de derivados cie ácido 2,3-diamìnopropiónico de fôrmula (l), en donde R1, R2 y R3 están definidos como en las reivindicaciones, por resoiución de racemato. La separación del racemato en sus enantiómeros tiene lugar a través de ia formación de saies diastereómeras al añadir un auxiliar enantioméricamente puro, y la separación subsiguiente mediante cristalización fraccionada.
DO2013000035A 2010-08-12 2013-02-11 Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico DOP2013000035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12
US201061428336P 2010-12-30 2010-12-30

Publications (1)

Publication Number Publication Date
DOP2013000035A true DOP2013000035A (es) 2013-03-15

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000035A DOP2013000035A (es) 2010-08-12 2013-02-11 Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico

Country Status (23)

Country Link
US (2) US8877926B2 (es)
EP (1) EP2603491B1 (es)
JP (1) JP6000248B2 (es)
KR (1) KR20130099044A (es)
CN (1) CN103209961A (es)
AR (1) AR082621A1 (es)
AU (1) AU2011288533A1 (es)
BR (1) BR112013002985A2 (es)
CA (1) CA2807979A1 (es)
CL (1) CL2013000420A1 (es)
CO (1) CO6690757A2 (es)
CR (1) CR20130059A (es)
DO (1) DOP2013000035A (es)
EC (1) ECSP13012434A (es)
GT (1) GT201300038A (es)
MA (1) MA34464B1 (es)
MX (1) MX2013001647A (es)
PE (1) PE20131326A1 (es)
RU (1) RU2013110525A (es)
SG (1) SG187791A1 (es)
TW (1) TW201221504A (es)
UY (1) UY33552A (es)
WO (1) WO2012019967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402461RA (en) 2011-12-06 2014-08-28 Sanofi Sa Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
AU2011288533A1 (en) 2013-02-28
US8877926B2 (en) 2014-11-04
JP6000248B2 (ja) 2016-09-28
ECSP13012434A (es) 2013-03-28
UY33552A (es) 2012-03-30
CO6690757A2 (es) 2013-06-17
BR112013002985A2 (pt) 2017-11-07
AR082621A1 (es) 2012-12-19
RU2013110525A (ru) 2014-09-20
CL2013000420A1 (es) 2013-04-05
EP2603491A1 (en) 2013-06-19
JP2013533296A (ja) 2013-08-22
KR20130099044A (ko) 2013-09-05
MX2013001647A (es) 2013-03-21
CA2807979A1 (en) 2012-02-16
WO2012019967A1 (en) 2012-02-16
CR20130059A (es) 2013-03-25
GT201300038A (es) 2015-06-24
PE20131326A1 (es) 2013-11-12
US20150018554A1 (en) 2015-01-15
CN103209961A (zh) 2013-07-17
TW201221504A (en) 2012-06-01
EP2603491B1 (en) 2014-09-24
US20130211085A1 (en) 2013-08-15
SG187791A1 (en) 2013-03-28
MA34464B1 (fr) 2013-08-01
US9434696B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
JOP20210064A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
PH12019502386A1 (en) Process for preparing s-containing pyrimidinium compounds
MX2018010199A (es) Proceso para la separacion de enantiomeros de derivados de piperazina.
EA201891642A1 (ru) Кристаллические формы ингибитора mdm2
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112018016789A2 (pt) processo para preparação biocatalítica e preparação de um composto
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
BR112019025028A2 (pt) Método para preparar um composto.
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
CL2020001049A1 (es) Proceso para producir compuestos de piridazinona herbicida.
AR085291A1 (es) Metodos para sintetizar derivados del precursor z de molibdopterina
EA201590116A1 (ru) Способ получения замещенных триазолопиридинов
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
DOP2013000035A (es) Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2013006017A (es) Separacion de enantiomeros derivados de triazina usando acido tartarico.
MX2018009544A (es) Metodo para preparar derivados de 4-aminoindano sustituido.
NI201300022A (es) Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3 - diaminopropiónico
TN2013000054A1 (en) Process for the preparation of enantiomeric forms of 2,3 - diaminopropionic acid derivatives